AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

832.129

+4.7150.57%

Number of Gainers:14

Number of Losers:12

Number of Flat:19

PE:- -

High:835.596

Open:827.558

Low:826.167

Close:827.414

Loading ...

Sector Update: Energy Stocks Fall Premarket Thursday

MT Newswires Live

BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug

What is next for ASX 200 shares after last month's upheaval?

Race Says No Adverse Events After First Patient Dosed with Drug Candidate in Tumor Trial; Shares Jump 14%

MT Newswires Live

Guess which ASX All Ords stock is rocketing 58% on big US news

Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%

MT Newswires Live

Imricor Medical Systems Says Hungary Hospital Performs First Atrial Ablations

MT Newswires Live

BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States

Dimerix Ltd - Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States

THOMSON REUTERS

Dimerix Ltd - Dimerix to Receive US$30 Mln Upfront Payment

THOMSON REUTERS

Actinogen Expects to Reach 100 Enrollments in Alzheimer's Disease Trial by Quarter-End

MT Newswires Live

BRIEF-Actinogen Provides Pivotal Alzheimer’S Trial Enrolment Update

Actinogen Medical Ltd - Alzheimer's Phase 2B/3 Trial Enrolls 60 Participants, Expects 100 by Quarter-End

THOMSON REUTERS

Actinogen Provides Pivotal Alzheimer’s Trial Enrolment Update and Other Business News

THOMSON REUTERS

Actinogen Medical Ltd - Final Results for 220 Participants Expected in Q4 2026

THOMSON REUTERS

Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news

Australia's CSL evaluates China tariff exemptions for its US-made drugs

Mesoblast Plans to Double Transplant Centers Onboarded for Graft Versus Host Disease Treatment

MT Newswires Live

Opthea Flags 'Going Concern' Uncertainty; Remains in Talks With Investors to Explore Possible Options

MT Newswires Live

BRIEF-Cann Group Posts Qtrly Production Of 1.53 Tonnes

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":832.1293,"timestamp":1746079199989,"preClose":827.41425,"halted":0,"volume":84946708,"delay":0,"changeRate":0.005699,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":4.715027,"latestTime":"05-01 16:00:00 AEST","open":827.5584,"high":835.596,"low":826.1665,"amount":132416245,"amplitude":0.011396,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746057600000,1746079200000]],"turnoverRate":0.002354,"increases":16,"decrements":10,"flats":17,"marketCap":132644128135.375,"floatMarketCap":129821126913},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":835.596,"amplitude":0.011396,"preClose":827.41425,"low":826.1665,"latestPrice":832.1293,"volume":84946708,"delay":0,"open":827.5584,"prevYearClose":936.801,"prevWeekClose":799.528,"prevMonthClose":827.414,"prevQuarterClose":815.605,"fiveDayClose":795.126,"twentyDayClose":815.605,"sixtyDayClose":919.481,"secType":"PLATE","market":"AU","turnoverRate":0.002354,"marketCap":132644128135.375,"floatMarketCap":129821126913,"timestamp":1746079199989,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":14,"down":12,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532070317","title":"Sector Update: Energy Stocks Fall Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070317?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:24","pubTimestamp":1746105856,"startTime":"0","endTime":"0","summary":"Energy stocks fell premarket Thursday with the Energy Select Sector SPDR Fund  0.9% lower recently.The United States Oil Fund  was down 0.8% and the United States Natural Gas Fund  was 0.3% higher.Front-month US West Texas Intermediate crude oil was down 0.9% at $57.69 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil lost 0.8% to $60.56 per barrel, and natural gas futures were 1.3% higher at $3.37 per 1 million British Thermal Units.TC Energy  shares fell by over 1% after the company reported a decline in Q1 comparable earnings from continuing operations.Antero Midstream  shares were up 0.7% after the company reported higher Q1 adjusted earnings and revenue.Targa Resources  shares were 0.5% lower after the company reported a decline in Q1 net income.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USO","BK7067","BK4588","IE00BMG7P926.USD","IE00BMG7P819.SGD","TRGP","LU0122376428.USD","TRP","TRP.AU","XLE","LU0788109394.HKD","BK4570","UCO","IE00BMG7P587.USD","IE00BMG7P694.USD","UNG","BK4144","BK4566","LU0456854461.SGD","BK7508","LU0266512127.USD","LU0368265418.SGD","BK4585","SCO","AM"],"gpt_icon":0},{"id":"2532049548","title":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2532049548","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532049548?lang=en_us&edition=fundamental","pubTime":"2025-05-01 12:23","pubTimestamp":1746073390,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020** Stock marks biggest intraday pct gain since October 5, 2023** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg** Last up 50%, DXB more than doubles YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nL4N3R909Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","LU2065171402.SGD","BK7067","FOLD","BK7508","BK4139","BK7501","LU2065169927.USD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2532904741","title":"What is next for ASX 200 shares after last month's upheaval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2532904741","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532904741?lang=en_us&edition=fundamental","pubTime":"2025-05-01 12:22","pubTimestamp":1746073324,"startTime":"0","endTime":"0","summary":"If the market did return to its April low, what are ASX 200 shares investors likely to do?It became clear very quickly during last month's volatility that many ASX investors were enthusiastically buying the dip. So, perhaps investors will grab a second opportunity to buy low with both hands.  Data from the online trading platform Stake showed investors targeted ASX large-cap shares during the April sell-off.  The t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/01/what-is-next-for-asx-200-shares-after-last-months-upheaval/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA.AU","BHP.AU","BK7148","BK7501","BK7507","BMR.AU","BK4023","BK7090","COL.AU","BK7007","CSL.AU","BK7042","FMG.AU","BK7082","BK7113","APA.AU","TCL.AU","BK7067","BK7104","BK7155","BK7087","GMG.AU","MGR.AU","XKO.AU","XJO.AU","TLS.AU","NEM.AU","BK7099","WOW.AU","BK7129","XAO.AU","BK7135","BK7511","NST.AU","BMR","GPT.AU","BK7510","BK7508","MQG.AU","BK7095","RMD.AU","BK7040","BK7046","RHC.AU","BK7506"],"gpt_icon":0},{"id":"2532012057","title":"Race Says No Adverse Events After First Patient Dosed with Drug Candidate in Tumor Trial; Shares Jump 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532012057","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532012057?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:37","pubTimestamp":1746063475,"startTime":"0","endTime":"0","summary":"Race Oncology  said no vein inflammation or any other adverse events were reported after its first patient was administered a dose of its drug candidate, reformulated bisantrene , in the phase one clinical trial for advanced solid tumor patients, according to a Tuesday filing with the Australian bourse.The trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 in combination with the chemotherapy drug doxorubicin, the filing said.Stage one will enroll up to 33 patients across multiple sites in Australia, Hong Kong, and South Korea, the filing added.After an interim analysis, the optimal dosage of RC220 combined with doxorubicin will be evaluated in an additional 20 patients in stage two of the trial, the filing added.Shares of the company jumped 14% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","BK7067","XJO.AU","RAC.AU","XAO.AU"],"gpt_icon":0},{"id":"2532108840","title":"Guess which ASX All Ords stock is rocketing 58% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2532108840","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532108840?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:13","pubTimestamp":1746062011,"startTime":"0","endTime":"0","summary":"The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher. In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news. Which ASX All Ords stock is rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/01/guess-which-asx-all-ords-stock-is-rocketing-58-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","FOLD","BK7508","BK7067","LU2065171402.SGD","LU2065170008.USD","LU2065169927.USD","BK7501","DXB.AU","FSGS","LU2065171311.SGD"],"gpt_icon":0},{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7067","FSGS","BK7501","DMX","BK7508"],"gpt_icon":0},{"id":"2532014342","title":"Imricor Medical Systems Says Hungary Hospital Performs First Atrial Ablations","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014342","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014342?lang=en_us&edition=fundamental","pubTime":"2025-05-01 08:56","pubTimestamp":1746060977,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  said Semmelweis University's Heart and Vascular Center in Hungary performed its first atrial flutter ablations guided by real-time magnetic resonance imaging, through the company's NorthStar 3D mapping system, according to a Thursday filing with the Australian bourse.The company aims for continued expansion and growth across Europe, including adding more sites to the VISABL-VT clinical trial, the filing said.Imricor Medical Systems shares rose past 2% in morning trade Thursday.Price : $1.66, Change: $+0.040, Percent Change: +2.47%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7503","IMR.AU","BK7508","BK7007"],"gpt_icon":0},{"id":"2532501587","title":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532501587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532501587?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:15","pubTimestamp":1746054919,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United StatesMay 1  - Dimerix Ltd DXB.AX:DIMERIX AND AMICUS THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR DMX-200 IN UNITED STATESDIMERIX TO RECEIVE US$30 MILLION UPFRONT PAYMENTDIMERIX TO RECEIVE UP TO US$560 MILLION FOR SUCCESS-BASED MILESTONE PAYMENTSFurther company coverage: DXB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065169927.USD","FOLD","LU2065171402.SGD","LU2065170008.USD","DXB.AU","BK7067","BK7508","BK7501","LU2065171311.SGD"],"gpt_icon":0},{"id":"2532130930","title":"Dimerix Ltd -  Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532130930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532130930?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2532015821","title":"Dimerix Ltd -  Dimerix to Receive US$30 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532015821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532015821?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2532131460","title":"Actinogen Expects to Reach 100 Enrollments in Alzheimer's Disease Trial by Quarter-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2532131460","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532131460?lang=en_us&edition=fundamental","pubTime":"2025-05-01 06:59","pubTimestamp":1746053969,"startTime":"0","endTime":"0","summary":"Actinogen Medical  has now enrolled 60 participants in its phase 2b/3 XanaMIA trial of Xanamem, its treatment candidate for Alzheimer's disease, and expects to reach 100 by the end of the quarter, triggering an interim data analysis, according to a Wednesday statement by the company.The trial targets Alzheimer's disease patients with elevated pTau181 levels, a biomarker linked to disease progression, to better detect Xanamem's treatment benefit.Final results for the full 220 participants are expected in the fourth quarter of 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2531031824","title":"BRIEF-Actinogen Provides Pivotal Alzheimer’S Trial Enrolment Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031824","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031824?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:07","pubTimestamp":1746014842,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Provides Pivotal Alzheimer’S Trial Enrolment UpdateApril 30 (Reuters) - Actinogen Medical Ltd ACW.AX:ACTINOGEN PROVIDES PIVOTAL ALZHEIMER’S TRIAL ENROLMENT UPDATE AND OTHER BUSINESS NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4WJ8L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2531674039","title":"Actinogen Medical Ltd - Alzheimer's  Phase 2B/3 Trial Enrolls 60 Participants, Expects 100 by Quarter-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2531674039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531674039?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4WJ8L7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"gpt_icon":0},{"id":"2531396310","title":"Actinogen Provides Pivotal Alzheimer’s Trial Enrolment Update and Other Business News","url":"https://stock-news.laohu8.com/highlight/detail?id=2531396310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531396310?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4WJ8L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2531039676","title":"Actinogen Medical Ltd - Final Results for 220 Participants Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039676?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4WJ8L7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2531030285","title":"Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news","url":"https://stock-news.laohu8.com/highlight/detail?id=2531030285","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531030285?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":"Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months later. SYDNEY, April 30, 2025  -- Actinogen Medical Limited  announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of this quarter. That milestone will trigger an interim analysis of available trial data by an independent Data Monitoring Committee approximately 6 months later. Final results for the full 220 participants are expected in Q4 2026.XanaMIA phase 2b/3 Alzheimer’s disease trial progress. “We are pleased with the positive and clear outcomes from our Type C meeting with the FDA on major depressive disorder  that provided excellent guidance for our Xanamem program.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-provides-pivotal-alzheimer-trial-120000938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2531876730","title":"Australia's CSL evaluates China tariff exemptions for its US-made drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531876730","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531876730?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:17","pubTimestamp":1746008273,"startTime":"0","endTime":"0","summary":"SHANGHAI  -Australia's CSL Ltd said it's evaluating whether its drugs used in surgery would be exempted from 125% tariffs China imposed on U.S.-made goods, as it seeks to minimise impact of a trade war between Beijing and Washington.China has granted tariff exemptions on select products, including select pharmaceuticals, and has also created a non-public list of goods that would be exempted from duties, Reuters reported earlier on Wednesday, in the clearest sign yet of Beijing's concerns about the trade war's fallout.The quiet approach allows Beijing, which has repeatedly said it is willing to fight until the end unless the U.S. lifts its 145% tariffs on Chinese imports, to maintain its public messaging while privately taking practical steps to provide concessions.\"We are aware of reports that certain goods imported from the U.S. into China are potentially being exempted from tariffs,\" a spokesperson for CSL told Reuters in a statement.\"We are working to determine the potential for our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/australias-csl-evaluates-china-tariff-101753571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XAO.AU","LU1169590202.USD","BK7067","BK4086","LU0728928796.USD","SGXZ23171101.USD","XJO.AU","BK7508","CSL.AU","XKO.AU","BK7501","CSL","BK7511","SG9999004303.SGD","LU1169589451.USD"],"gpt_icon":0},{"id":"2531771066","title":"Mesoblast Plans to Double Transplant Centers Onboarded for Graft Versus Host Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531771066","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531771066?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:17","pubTimestamp":1745993866,"startTime":"0","endTime":"0","summary":"Mesoblast  onboarded ten transplant centers in the US for the supply of Ryoncil for the treatment of steroid-refractory acute graft versus host disease during the March quarter, and the firm plans to recruit ten more priority transplant centers during the June quarter, according to a Wednesday Australian bourse filing.The firm brought on board a team of nine key account managers in the last week of April, who will focus on onboarding the remaining 35 priority transplant centers, accounting for 80% of US pediatric transplants.It also secured a Type B meeting with the US Food and Drug Administration scheduled for the June quarter to discuss the accelerated approval pathway for Revascor, a candidate for the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.Its shares fell 2% in recent trading on Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","MSB.AU","BK4218","BK4585","BK4139","BK7508","BK7501","HST","MESO","BK4181","BK4588"],"gpt_icon":0},{"id":"2531720686","title":"Opthea Flags 'Going Concern' Uncertainty; Remains in Talks With Investors to Explore Possible Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720686","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531720686?lang=en_us&edition=fundamental","pubTime":"2025-04-30 12:43","pubTimestamp":1745988212,"startTime":"0","endTime":"0","summary":"Opthea  said that there remained material uncertainty as to its ability to continue as a \"going concern,\" according to a Wednesday Australian bourse filing.The company noted it continues an active discussion with investors as required by a development funding agreement to explore possible options to deliver the best outcome for the firm and its shareholders.The firm said it plans to use the net proceeds from any current or future offering or capital raise to advance clinical development, chemistry, manufacturing and controls, regulatory activities of any new asset, and for general corporate purposes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK7508","OPT","BK4139","BK7067","ISBC","BK4211"],"gpt_icon":0},{"id":"2531874182","title":"BRIEF-Cann Group Posts Qtrly Production Of 1.53 Tonnes","url":"https://stock-news.laohu8.com/highlight/detail?id=2531874182","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531874182?lang=en_us&edition=fundamental","pubTime":"2025-04-30 09:19","pubTimestamp":1745975998,"startTime":"0","endTime":"0","summary":"BRIEF-Cann Group Posts Qtrly Production Of 1.53 TonnesApril 30 (Reuters) - Cann CAN.AX:QTRLY  PRODUCTION OF 1.53 TONNESQTRLY  SALES OF A$2.33MFurther company coverage: CAN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R802T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CAN.AU","BK7502","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":100,"code":"91000000","status":"200"}]}}